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A B S T R A C T
Objective: Long-term lamivudine (LAM) and adefovir (ADV) treatment has been found to induce the
emergence of drug-resistant hepatitis B virus (HBV) in a signiﬁcant number of patients with chronic
hepatitis B (CHB) infection. The aim of our studywas to evaluate the LAM and ADVmutations detected in
our patient group.
Materials and methods: Twenty-four patients diagnosed with CHB were enrolled in this study. The
patient group consisted of those who had received 6months of treatment with interferon-a andwho did
not response to this therapy. Patients were evaluated based on virologic and serologic response to
therapy, and were classiﬁed as responders or non-responders. The treatment of non-responders
continued with LAM (3 mg/kg/d, maximum 100 mg/d). Due to a lack of response to treatment, ADV
(10 mg/g) was added to the treatment regimen of eight young adult patients. The mutations associated
with HBV drug resistance were investigated using reverse hybridization methods and PCR.
Results: The mutation studies indicated that 14 (58.4%) of the patients had resistance. Three patients
developed ADV-associated mutations (A181T), one after 18 months of ADV; the other two had
undergone 18 and 36 months of LAM therapy without ADV exposure. Although the average LAM
treatment period of the patients with LAM resistance was longer than for those in whom no resistance
was detected, no statistically signiﬁcant difference was found.
Conclusions: HBV treatment with nucleoside analogues results in the development of mutant strains,
leading to drug resistance. Therefore genotypic resistance testing is important in planning and
monitoring HBV treatment.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Infection with the hepatitis B virus (HBV), which is known to
affect approximately 400 million people, is a global health issue.
HBV infection not only results in acute, fulminant, and chronic
hepatitis, but it may also contribute to the development of hepatic
cirrhosis and hepatocellular carcinoma in the long-term.1 The
dominant viral strain in the majority of children diagnosed with
chronic hepatitis B (CHB) is wild-type HBV during the normal
development phase of the infection. Mutant viruses may be
reported in the periods before and after hepatitis B e antigen
(HBeAg) seroconversion in the long-termobservation of patients. It
is also possible that patients become infected primarily with the
mutant strain of the virus. In addition, nucleoside analogs utilized
in therapy are known to induce the formation of mutant strains.2* Corresponding author. Tel.: +90 232 463 43 32; fax: +90 232 433 07 56.
E-mail address: sezin.akman@gmail.com (S.A. Akman).
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doi:10.1016/j.ijid.2009.04.002The approved therapy options for childhood CHB infections are
interferon-a (IFN-a) and lamivudine (LAM), which is a nucleoside
analog. Currently, adefovir (ADV) may be added to the therapy
options in children.3 The correct duration of LAM therapy, which
has been evaluated safe in terms of side effects, is not yet clear. The
safety and efﬁcacy of LAM use for a duration of one year has been
established in children aged 2 years. Favorable outcomes from
LAM treatment of CHB in children are maintained for at least
several years after completion of treatment. Up to 3–4 years of LAM
treatment is safe in children.4 Considering the safety of LAM, it has
been suggested that continuous therapy may be beneﬁcial,
particularly in patients who do not show HBeAg seroconversion.5
LAM therapy is discontinued in patients who do not respond to
treatment and this results in an increase in HBV-DNA levels. The
results of studies have shown that a sustained response with
HBeAg to anti-hepatitis B e antibody (anti-HBe) seroconversion is
rarely obtained, and hepatitis B surface antigen (HBsAg) loss is
seldom seen.6 Another risk of the drug is the possibility of the
development of drug-resistant mutations.7–10 Long-term LAMses. Published by Elsevier Ltd. All rights reserved.
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of resistance.5,7,11 Resistance to LAM is associated with mutations
in the HBV polymerase gene. The most frequent mutation
developing with LAM is the YMDD (tyrosine–methionine–aspar-
tate–aspartate) mutation of the HBV polymerase gene, which is
reported to be found in 19% of children subjected to therapy.2,12
These mutations usually affect the YMDDmotif located in the C
domain of the HBV reverse transcriptase (rt), by replacement of a
methionine residue at position 204 with either valine or
isoleucine.5,7
Another nucleoside analog which is used in the treatment of
CHB in adulthood and childhood is ADV. ADV therapy which is
administered orally like LAM, should be closelymonitored in terms
of long-term nephrotoxicity, and is known to be effective on
viruses that are resistant to LAM. The frequency of resistance to
ADV, which is known to be effective on HBeAg-negative and wild-
type HBV infections, is low.3,13
As studies onmutation proﬁles in children and young adults are
limited, the purpose of this study was to investigate drug
resistance developing during the treatment process in patients
with CHB.
2. Materials and methods
This study investigated mutations that developed against
nucleoside analogs in 24 patients who were diagnosed with
CHB infection, whowere undergoing LAM and ADV therapy as they
had not responded to 6months of IFN-a. Our study was performed
prospectively between July 2005 and July 2007. Data recorded for
this study were based on retrospective review of the medical
records for the period 2003–2005. The baseline patient character-
istics were measured prior to LAM therapy.
Patients monitored in the pediatric gastroenterology and
hepatology units and the infectious diseases and clinical micro-
biology departments, and (1) whose HBsAg and HBeAg were
positive, (2) whose HBV-DNA level was over 1  105 copies/ml, (3)
whose alanine aminotransferase (ALT) level was 1.5 times higher
than normal for 6 months (upper limit 40 IU/l), and (4) who were
reportedwith amoderate or acute effect on the liver on ﬁne-needle
biopsy (Knodell activity index>4 or ﬁbrosis2)14were included in
the study, in addition to patients (1) whose HBeAg was negative,
(2) whose HBV-DNA level was over 1 104 copies/ml, and (3) who
were reported to be acutely or moderately affected according to
biopsy, as well as patients who were scheduled to be subjected to
CHB infection treatment as their ALT level was found to be high.
Exclusion criteria were: age less than 2 years, platelet count less
than 150  109/l, white blood cell count less than 3  109/l,
hemoglobin levels below 10 g/dl, existence of renal failure, hepatic
decompensation or psychiatric disorders, any accompanying cause
of chronic liver disease other thanHBV, and central nervous system
disease such as epilepsy. The participants of the study were not co-
infected with hepatitis C virus, hepatitis D virus, or HIV.
The patient group was made up of individuals who were
administered IFN-a (IFN-a2b (Intron A), Schering Plough) therapy
in the ﬁrst phase (5 million units/m2, with a maximum dose 10
million units, given three times a week, subcutaneously for 6
months) and who did not respond to this therapy.
Therapy efﬁcacy measures included HBeAg loss or seroconver-
sion, undetectable HBV-DNA, ALT normalization, andHBsAg loss or
seroconversion. Patients whose ALT levels did not reach their
normal values, whose HBV-DNA levels did not reduce, and who
were not reported with HBeAg seroconversion were regarded
irresponsive to treatment. These patients underwent LAM therapy
(Zefﬁx, GlaxoSmithKline; 3 mg/kg/g, maximum 100 mg/g, oral).
LAM therapy was continued until loss of HBeAg or seroconversion
in patients who had not responded to the therapy. During LAMtherapy, in the case of irresponsiveness or the loss of response to
treatment, the current situationwas to be evaluated in conjunction
with the infectious diseases unit. We used the same criteria for
response to IFN-a and LAM/ADV treatment: ‘responders’ were
deﬁned as those cases with undetectable HBV-DNA, ALT normal-
ization, and HBeAg/HBsAg loss or seroconversion. If these
parameters were not found, the patients were deﬁned as ‘non-
responders’.In the case of non-responders, ADV (Hepsera, Er-Kim;
10 mg/g, oral) was added to the treatment schedule of eight
patients who were over 18 years of age; ADV was not approved for
use in children under the age of 18 in our country. The follow-up
period for the patients was changed from 26 to 54months. Adverse
events were not determined during LAM and ADV therapy and
there was no treatment discontinuation.
During the course of antiviral therapy, cases were re-evaluated
with complete blood count and ALT valuesmonthly during the ﬁrst
two months, and after the third month they were re-evaluated
with complete blood count and ALT values, and serologic studies
once every three months. Quantitative HBV-DNAwas studied once
every six months. There was no patient who suffered from renal
insufﬁciency, so dosing adjustments for both LAM and ADV were
not required for renal insufﬁciency.
Mutations that developed according to the nucleoside analog
treatment administered in the 24 patients were investigated
prospectively and their drug resistance was evaluated. Measure-
ment of drug resistance was undertaken once at 20–24 months of
LAM treatment. The mutation evaluations were carried out before
ADV treatment in these patients.
Upon obtaining written informed consent from the patients’
families in the case of those aged under 18 years and from the
patients whowere aged 18 years and over, 2 ml of bloodwas taken
from each patient and sera were kept at under 20 8C before
examination at the Infectious Diseases Clinical Microbiology
Molecular Diagnosis Laboratory.
Mutations in the HBV-DNA polymerase gene were determined
using PCR and reverse hybridization.
Drug resistance mutations were determined using the Innoge-
netics Inno-Lipa HBV DR assay according the manufacturer’s
recommendations. The ampliﬁcation reactions were performed as
follows: the ampliﬁcation reaction contained 1ml each of
25mmol/l speciﬁc primers (Inno-LipaHBVDR, Innogenetics Ghent,
Belgium), 1ml 10 mmol/l dNTP mixture, 1ml 25 mmol/l MgCl2,
0.4 ml Taq DNA polymerase (Qiagen, Inc., Hilden, Germany), and
5ml 10 PCR buffer solution. The total volume was brought up to
50 ml using ddH2O.
After ampliﬁcation, the biotinylated DNA material generated
from the HBV polymerase gene was hybridized with speciﬁc
oligonucleotide probes immobilized as parallel lines on mem-
brane-based strips.
HBsAg, HBeAg, and anti-HBe antibodies were examined on the
basis of the ELISA method (DiaSorin S.p.A. Saluggia, Italy). HBV-
DNA (Roche Molecular Systems, Inc, Branchburg, NJ, USA) was
applied to determine the viral load.
SPSS version 13.0 (SPSS Inc., Chicago, USA) was used for
statistical analyses. Mean, median, standard deviation, minimum
and maximum values were taken into account in the evaluation of
viral load. A p-value of <0.05 was accepted as statistically
signiﬁcant.
3. Results
The average age of the 24 patients monitored in the pediatric
gastroenterology and infectious diseases polyclinics as a result of
diagnosis with CHB was 12.9  4 years (median 12, range 6–20
years); 10 (41.7%) of these patients were female. Two of the patients
were reported HBeAg-negative, anti-HBe-positive, and HBV-DNA-
Table 1
Patient characteristics.
Total number of patients (N) 24
Age, yearsa 12 (6–20), 12.9  4
Gender, M/F (n (%)) 14/10 (58.3/41.7)
Age at diagnosis, yearsa 6 (3–14), 6.9  2.9
Disease duration, yearsa 6 (1–12), 5.9  2.9
ALT, IU/la 96 (49–278), 105  43.2
HAIa 9 (6–16), 9.5  3
LAM therapy, monthsa 32.5 (12–48), 32.3  8.3
ADV therapy, monthsa,b 23 (12–24), 22.2  5
Drug resistance, n (%) 14 (58.3)
M, male; F, female; ALT, alanine aminotransferase; HAI, hepatic activity index;
LAM, lamivudine; ADV, adefovir; SD, standard deviation.
a Results are median (range), mean  SD.
b ADV treatment was given to eight patients.
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HBsAg and HBeAg-positive was 12.5  3.9 years; their ALT level was
105  43.2 IU/l and the average of their viral load was 1  107 copies/
ml. HBeAg seroconversion developed in the last ﬁve months as a
consequence of LAM therapy in ﬁve (20.8%) patientswhose treatment
duration was 32.3  8.3 months; eight cases whose ages were
appropriate were administered ADV therapy.
During LAM therapy, 22 (91.7%) patients had ALT normal-
ization and 10 (41.7%) patients had decreased HBV-DNA levels.
LAM + ADV combination therapy was used in eight patients in
whom ALT normalization was determined in seven and HBV-
DNA clearance in ﬁve. The average duration of LAM therapy in
previous applications in these eight patients was 36  9.1
months, while the duration of ADV therapy was found to be
22.2  5 months (Table 1).
While no mutation was determined in 10 patients (41.6%), it
was found that one patient out of threewhowere diagnosedwith a
mutation with regards to ADV, developed rt181T mutation
following 18 months of ADV therapy; the other two developed
mutations without ADV therapy. Among patients who were
reported to have resistance to nucleoside analogs, eight patients
were reported with rt80I mutation, six patients with rt204YMD-
D+YVDD mutation, ﬁve patients with rt180 M mutation, four
patients with rt204YMDD+YIDD mutation, three patients with
rt181T mutation, two patients with rt80 V mutation, and one
patient was reportedwith rt173L, one with rt180FLL+FLM, and one
with rt204YMDD+YVDD+YIDD mutations (Table 2). The presence
of three or more mutant strains observed in 10 patients (71.4%)
among a total of 14 patients was regarded as considerable.
Although the average LAM therapy duration of the 12 patients
having a single resistance to LAMwas higher than in the group thatTable 2
Detected mutations and treatment periods in subjects with chronic hepatitis B.
No. Case LAM therapy (months) ADV th
1 M.D. 48 18
2 M.T. 36 24
3 A.G. 36 12
4 M.O. 24 18
5 T.O. 36 -
6 G.D. 24 -
7 S.M. 48 12
8 E.Y. 24 -
9 Y.E. 36 -
10 E.P. 36 -
11 S.K. 36 -
12 B.K. 24 -
13 H.M. 20 -
14 E.D. 18 -
LAM, lamivudine; ADV, adefovir.
* ADV-associated mutations.was reported not to have any resistance, the difference was not
statistically signiﬁcant (p > 0.05).
4. Discussion
It is known that the use of nucleoside analogs in CHB infected
patients increases the probability of mutant strain development in
HBV. Mutations developing in HBV can be regarded as a protection
method developed by the virus in order to create resistance to the
immune system and/or to the treating agent, as seen in all societies
in the world. Especially high mutation rates are determined in the
polymerase gene of HBV. It is thought that HBV mutations play an
important role in the natural development of HBV and contribute
to the continuation of infections caused by viral genetic
modiﬁcations.2,10,15
Nucleoside analogs such as LAM and ADV induce a decrease in
serum HBV-DNA levels associated with normalization of serum
ALT levels. But their sustained response with HBeAg to anti-HBe
seroconversion is rarely seen, as in some other studies.6,9,13
In a multicenter study conducted by Jonas et al., which
compared LAM therapy and placebo, the 19% mutation rate found
in the group that had undergone LAM therapy may be accepted as
an indicator of drug resistance that developed during treatment
with nucleoside analogs. This study involved 191 children
diagnosed with CHB; no mutation was observed in the HBV
polymerase gene in the placebo group during the ﬁrst year of
treatment.8 On the other hand, in a study of LAM therapy in
children of HBV carrier mothers, YMDDmutants developed in 34%
of the LAM treated children after one year of therapy.16
As a result of a three-year LAM therapy in 429 patients, the
frequency of YMDD mutation development per annum was
calculated as 12.1%, 49.7%, and 70.5% in the ﬁrst, second, and
third years, respectively.17 The ﬁndings of our study are in parallel
with the literature, as mutations were observed in 58.4% of the
total 24 patients whose LAM therapy duration was 30.2  10.2
months. No statistically signiﬁcant difference was determined
between lengthening of the treatment and the development of
mutations (p = 0.347), but it was reported that LAM therapy duration
in patients with drug resistance was longer than in the group with no
reported resistance (31.8  9.6 vs. 27.9  10.9).
Adefovir is stated to be effective in LAM-resistant mutations.
Genotypic resistance rates of 1%, 2%, 4%, and 4% were
determined for each year of ADV therapy.18,19 There are also
previous studies in which ADV resistance was found to be 0% at
sixth months, 6.5% in the ﬁrst year, and 24.6% at 18 months. The
mutation development rate is lower when compared to LAM
therapy and also occurs later. The mutation development rate inerapy (months) Mutations
rtL80 I, rtL180 M, rtM204I YMDD+YIDD
rtM204I YMDD+YVDD
rtL180 M, rtM204I YMDD+YVDD
rtA181 T*
rt180 FLL+FLM, rtM204I YMDD+YIDD
rtL80 I
rtL80 I, rtV173 L, rtL180 M, rtM204I YMDD+YVDD
rtL80 I, rtM204I YMDD+YVDD
rtL80 I, rtL180 M, rtM204I YMDD+YVDD+YIDD
rtL80 V, rtL180 M, rtM204I YMDD+YVDD
rtA181 T*
rtL80 I, rtL180 M, rtM204I YMDD+YVDD
rtL80 I, rtM204I YMDD+YIDD
rtL80 I+V, rtM204I YMDD+YIDD, rtA181 T*
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high. In a study conducted by Chen et al., the cumulative
incidence of ADV resistance at months 6, 12, 18, and 24 was 0%,
6.5%, 24.6%, and 38.3%, respectively.20
The average ADV therapy duration for the eight patients who
were aged between 18 and 20 years was determined to be 22.5  5
months. While the mutation rate with LAM therapy was 56.2%, the
mutation rate with ADV therapy was 62.5%.
In YMDDmutation, isoleucine or valine replaced methionine in
the YMDD pattern of DNA polymerase dependent on RNA in the
HBV-resistant strain. There are also other mutations in which
methionine and serine are replaced in the YMDD pattern and
leucine and methionine are replaced in the amino acid substitu-
tions in codon 180 and codon 181.21,22 The mutation proﬁle was
heterogeneous in the patient group made up of 24 patients, all of
whom were reported with genotype D. rt80 I/V, rt204 YMDD/
YVDD/YIDD, rt180 M/ FLL+FLM, and rt173 L mutations were
observed in various combinations. In a study conducted in Turkey
on the evaluation of LAM resistance before treatment in CHB
patients, 7.8% of 77 patients with genotype D were reported with
the tyrosine–methionine–aspartate–aspartate patterned muta-
tion.23 In non-Turkish studies in which the relationship between
genotypic characteristics and mutations has been investigated, no
difference was observed in the YMDD mutation parameters.24
Recent clinical research associates the virological irrespon-
siveness developed during LAM or ADV therapy and the
replacement of amino acids at position 181 of HBV polymerase.
It has also been reported that this amino acid replacement induces
the cross-resistance to LAM and ADV, and investigators have
drawn attention to the importance of genotypic and phenotypic
analysis of antiviral drug resistance.25 According to the study by
Gaia et al., the existence of the rt181mutationmay be an indicator
of HBV-DNA positivity and can be associated with irresponsive-
ness to treatment.26 In the study conducted by Lampertico et al.,
the rtA181 V/T mutation was observed in six of 145 patients
before treatment for whom ADV therapy was planned because of
irresponsiveness to LAM therapy, whereas three patients were
reported with rtA181T in the course of treatment.19 On the other
hand, within our patient group, three patients were reportedwith
the rt181Tmutation associatedwith ADV. It was found that one of
these patients underwent ADV therapy for 18 months; however,
the other two patients underwent LAM therapy for 18 or 36
months without undergoing ADV therapy. This situation was
thought have arisen as a result of cross-resistance due to
nucleoside analog treatments. Lamivudine resistance has been
found to confer cross-resistance to some of these compounds and
it is likely that resistance to other antivirals may also develop
during prolonged use. Drug resistance therefore poses a major
threat to nucleoside analogue-based therapies for chronic HBV
infection.24,26
In our study, the rate of mutations that developed as a result of
the use of nucleoside analogs in the course of treatment, resulting
in drug resistance, was found to be 60%. As the development of
mutant viruses affects the prognosis of the disease negatively by
hindering the success of treatment, it is important to investigate
these mutations. If mutant strains are to be determined, this will
facilitate other treatments with no resistance development to
viruses and with stable antiviral effects.Conﬂict of interest: No conﬂict of interest to declare.
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